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PAtherosclerosis
ssociation Among Plasma
evels of Monocyte Chemoattractant
rotein-1, Traditional Cardiovascular
isk Factors, and Subclinical Atherosclerosis
ajat Deo, MD,* Amit Khera, MD,* Darren K. McGuire, MD, MHSC,* Sabina A. Murphy, MPH,†
anuario de P. Meo Neto, MD,‡ David A. Morrow, MD, MPH,† James A. de Lemos, MD*
allas, Texas; Boston, Massachusetts; and Sao Paulo, Brazil
OBJECTIVES We sought to evaluate the association between plasma levels of monocyte chemoattractant
protein (MCP)-1 and the risk for subclinical atherosclerosis.
BACKGROUND Monocyte chemoattractant protein is a chemokine that recruits monocytes into the devel-
oping atheroma and may contribute to atherosclerotic disease development and progression.
Plasma levels of MCP-1 are independently associated with prognosis in patients with acute
coronary syndromes, but few population-based data are available from subjects in earlier
stages of atherosclerosis.
METHODS In the Dallas Heart Study, a population-based probability sample of adults in Dallas County
65 years old, plasma levels of MCP-1 were measured in 3,499 subjects and correlated with
traditional cardiovascular risk factors, high-sensitivity C-reactive protein (hs-CRP), and
coronary artery calcium (CAC) measured by electron beam computed tomography.
RESULTS Higher MCP-1 levels were associated with older age, white race, family history of premature
coronary disease, smoking, hypertension, diabetes, hypercholesterolemia, and higher levels of
hs-CRP (p  0.01 for each). Similar associations were observed between MCP-1 and risk
factors in the subgroup of participants without detectable CAC. Compared with the subjects
in the lowest quartile of MCP-1, the odds of prevalent CAC (CAC score 10) for subjects
in the second, third, and fourth quartiles were 1.30 (95% confidence interval [CI] 0.99 to
1.73), 1.60 (95% CI 1.22 to 2.11), and 2.02 (95% CI 1.54 to 2.63), respectively. The
association between MCP-1 and CAC remained significant when adjusted for traditional
cardiovascular risk factors, but not when further adjusted for age.
CONCLUSIONS In a large population-based sample, plasma levels of MCP-1 were associated with traditional
risk factors for atherosclerosis, supporting the hypothesis that MCP-1 may mediate some of
the atherogenic effects of these risk factors. These findings support the potential role of
MCP-1 as a biomarker target for drug development. (J Am Coll Cardiol 2004;44:1812–8)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.047© 2004 by the American College of Cardiology Foundation
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nonocytes/macrophages play a fundamental role in the
nitiation, progression, and complications of coronary ath-
rosclerosis (1,2). Monocyte chemoattractant protein
MCP)-1 is the primary chemokine responsible for the
ecruitment of monocytes to sites of active inflammation,
ncluding the developing atheroma (3). In addition, MCP-1
ctivates monocytes to express tissue factor and superoxide
nions (4,5), which may contribute to plaque instability and
he development of acute coronary syndromes.
Mice susceptible to atherosclerosis that undergo targeted
eletion of either the MCP-1 (6) or the MCP-1 receptor
CCR-2) gene (7) have less monocyte accumulation and
educed atherosclerotic plaque burden when fed a cholesterol-
From the *Donald W. Reynolds Cardiovascular Clinical Research Center, Univer-
ity of Texas Southwestern Medical Center, Dallas, Texas; †Donald W. Reynolds
ardiovascular Clinical Research Center, Brigham and Women’s Hospital, Boston,
assachusetts; and ‡INCOR, Sao Paulo, Brazil. The MCP-1 assays were provided
t no charge by Biosite Inc. (San Diego, California). Drs. de Lemos and Morrow have
eceived consulting fees from Biosite Inc.a
Manuscript received March 11, 2004; revised manuscript received July 4, 2004,
ccepted July 28, 2004.ich diet compared to mice without targeted deletion of
hese genes. In human autopsy specimens, MCP-1 expres-
ion has been demonstrated within atheromatous lesions
8). More recently, investigators have focused on circulating
lasma levels of MCP-1 as a biomarker with potential
linical utility. Results from one large prospective study
emonstrated an independent association between plasma
evels of MCP-1 and clinical outcomes in patients with
cute coronary syndromes (9). In this study, MCP-1 levels
ere also strongly associated with several traditional cardio-
ascular risk factors such as age, hypercholesterolemia,
ypertension, diabetes, and renal insufficiency. These asso-
iations with atherosclerosis risk factors suggest that
CP-1 may also be an important biomarker earlier in the
isease process, during the preclinical phase of atheroscle-
osis. Although small studies have reported an association
etween plasma MCP-1 levels and the extent of coronary
therosclerosis among patients with unstable angina (10),
o studies have evaluated the association between MCP-1
nd subclinical atherosclerosis.
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November 2, 2004:1812–8 MCP-1 and Coronary AtherosclerosisGiven the multiple lines of experimental evidence impli-
ating MCP-1 in atherogenesis, and the association be-
ween plasma MCP-1 levels and cardiovascular risk factors
bserved in clinical studies, we sought to determine whether
lasma MCP-1 levels correlate with subclinical atheroscle-
osis. In addition, we sought to clarify the associations
etween MCP-1 levels and traditional cardiovascular risk
actors using data from the Dallas Heart Study, a large and
ell-phenotyped population-based sample.
ETHODS
tudy population. The Dallas Heart Study is a population-
ased, multiethnic probability sample of 6,101 subjects in
allas County designed to study cardiovascular disease. Details
f the study design and characteristics of the enrolled cohort
ave been described previously (11). Briefly, a stratified ran-
om sample of Dallas County residents age 18 to 65 years was
btained from a pool of 841,943 eligible subjects using the U.S.
ostal Service Delivery Sequence File, with deliberate over-
ampling of African Americans. An initial visit for 6,101
articipants included a detailed in-home interview for demo-
raphic and health-related data, as well as measurements of
eight, heart rate, and five sequential blood pressure measures.
ll subjects between the ages of 30 and 65 years who
ompleted the initial visit were invited to return for a second
isit to collect fasting venous blood and urine samples. If they
ompleted the second visit they were invited to return for a
hird detailed clinic visit, consisting of a 12-lead electrocardio-
ram, cardiac and aortic magnetic resonance imaging, electron
eam computed tomography (EBCT) to assess coronary artery
alcification, and dual-energy X-ray absorbiometry scanning to
valuate fat distribution and bone density. A total of 3,557
ubjects completed the second visit, and 2,971 subjects com-
leted the third visit. No significant differences were noted in
emographics, medical history, blood pressure, or body mass
ndex between subjects participating in the home interview and
he phlebotomy visit. Moreover, laboratory values were similar
etween those participating in the phlebotomy and clinic visits
11).
CP-1 assay. Blood samples were obtained after an over-
ight fast in EDTA tubes and were stored for 4 h at 4°C
efore processing. Plasma aliquots were frozen at 80°C
ntil assays were performed. Monocyte chemoattractant
rotein-1 measurements were performed in duplicate on
Abbreviations and Acronyms
CAC  coronary artery calcium
CAD  coronary artery disease
EBCT  electron beam computed tomography
HDL  high-density lipoprotein
hs-CRP  high-sensitivity C-reactive protein
LDL  low-density lipoprotein
LVEF  left ventricular ejection fraction
MCP  monocyte chemoattractant proteinhawed samples at Biosite Inc. (San Diego, California) on a righ-throughput robotic platform (TECAN Genesis RSP
00/8). Details of the MCP-1 immunoassay have been
reviously reported (9). The minimal detectable concentra-
ion for the assay is 40 pg/ml, and the upper end of the
eportable range is 2,000 pg/ml.
BCT scans. Electron beam computed tomography mea-
urements were performed on 2,763 subjects who were 30
ears old. Measurements were obtained at 80% of the RR
nterval using an Imatron 150 XP (Imatron Inc., San Bruno,
alifornia), 30 cm FOV, 512 matrix with sharp kernel
econstruction. Calcium scoring followed the protocol of
he Multi Ethnic Study of Atherosclerosis (12), and detec-
ion of calcium was based on a focus of calcium with 3
ontiguous pixels and a computed tomography threshold of
30 Hounsfield units. Electron beam computed tomogra-
hy scores were expressed in Agatston units (13,14) and the
ean of two consecutive scans was used as the final EBCT
core, unless only one scan was obtained. To minimize
alse-positive coronary artery calcium (CAC) classifications
ue to tissue-associated artifact, a mean EBCT score 10
gatston units was defined as CAC-positive status in this
tudy; at 10 Agatston units, more than 95% of subjects were
oncordant for positive (10) or negative (10) scores in
he replicate EBCT scans.
efinitions of variables. Complete medication profiles
ere obtained at the first visit. Hypercholesterolemia was
efined as a calculated low-density lipoprotein (LDL)
holesterol 160 mg/dl on a fasting sample, direct LDL
160 mg/dl on a non-fasting sample, total cholesterol
240 mg/dl, or use of statin medication. Hypertriglyceri-
emia was defined as a fasting triglyceride concentration
200 mg/dl and low high-density lipoprotein (HDL) was
efined as HDL 40 mg/dl in men and  50 mg/dl in
omen. Five sequential blood pressure measurements were
veraged for the first subject visit. Hypertension was defined
s an average systolic blood pressure 140 mm Hg and
iastolic blood pressure 90 mm Hg or use of antihyper-
ensive medication. Diabetes was defined by a fasting
lucose level 126 mg/dl or use of any hypoglycemic
edication. C-reactive protein measurements were per-
ormed using a commercially available high-sensitivity assay
Roche Diagnostics, Indianapolis, Indiana).
tatistical analysis. Categorical data are reported as pro-
ortions and continuous data as median values with inter-
uartile ranges (25th to 75th percentile). Baseline demo-
raphic variables and cardiovascular risk factors were
ompared across quartiles of MCP-1 using the chi-square
rend test for categorical variables and the test for trend
cross ordered groups for continuous variables. The associ-
tions between MCP-1 levels and continuous variables were
xplored using Spearman correlation coefficients, without
djustment for lipid-lowering or antihypertensive therapies.
ultivariate linear regression analysis was used to identify
ariables independently associated with log MCP-1 levels.
og MCP-1 levels were used in this analysis because of aightward skew of MCP-1 values. Associations between
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MCP-1 and Coronary Atherosclerosis November 2, 2004:1812–8CP-1 quartiles and CAC were determined using a series
f univariable and multivariable logistic regression models,
ith adjustment for traditional risk factors and for age. The
rend across MCP-1 quartiles was evaluated using the test
or linear trend of the log odds.
ESULTS
n the Dallas Heart Study, 3,499 patients (mean age 44 
0 years) underwent measurement of MCP-1 levels. The
edian MCP-1 concentration was 167.9 pg/ml, and the
5th, 75th, 90th, and 95th percentiles were 123.1, 226.1,
04, and 380.5 pg/ml, respectively. Of these 3,499 patients,
,723 had EBCT scans performed to measure CAC scores.
oronary artery calcium was present (CAC score 10) in
72 patients and absent in 2,151 patients.
ssociation with baseline risk factors. In univariable
nalyses, increasing quartiles of MCP-1 were associated
ith older age, white race, hypertension, diabetes, smoking,
amily history of coronary artery disease (CAD), lower
reatinine clearance, and higher levels of LDL cholesterol,
riglycerides, and CRP. In contrast, there was no association
ith left ventricular hypertrophy, left ventricular dysfunc-
ion, or the total percent of body fat (Table 1). In the
ubgroup of patients without detectable coronary calcifica-
ion (CAC 10), similar associations were observed be-
ween quartiles of MCP-1 and older age, white race,
ypertension, smoking, family history of CAD, lower cre-
tinine clearance, and higher triglyceride and CRP levels
able 1. Association Between MCP-1 Levels and Demographic
Quartile 1 Quar
ubjects (n) 875 8
ange (pg/ml) 123.1 123.2
ge (yrs) 40 [34, 48] 43 [36
ale gender 363 (42) 423
ace
Black 526 (60) 423
White 192 (22) 265
Hispanic 140 (16) 171
Other 17 (2) 18
edical history
Hypertension 246 (28) 270
Diabetes 73 (8) 97
Cholesterol (mg/dl) 172 [150, 198] 176 [15
Triglycerides (mg/dl) 82 [60, 127] 96 [66
HDL (mg/dl) 48 [41, 59] 47 [40
LDL (mg/dl) 101 [82, 124] 103 [83
Current smoker 218 (25) 232
Family history of CAD 258 (29) 278
CrCl (ml/min) 118 [99, 144] 118 [10
LVH (n  2,746) 91 (13) 82
LVEF 55% (n  2,746) 20 (3) 15
BMI 28 [24, 33] 28 [25
% fat by DEXA 32 [25, 40] 33 [25
Median hs-CRP (mg/l) 2.4 [1, 6.1] 2.7 [1.
ategorical data are presented as number (percent) and continuous data are presente
BMI  body mass index; CAD  coronary artery disease; CrCl  creatinine c
holesterol; hs-CRP  high sensitivity C-reactive protein; LDL  low-density lip
ypertrophy; MCP-1  monocyte chemoattractant protein-1.Table 2). cWhen MCP-1 was considered as a continuous variable,
ignificant correlations were observed with age, systolic
lood pressure, total cholesterol, LDL, HDL, triglycerides,
nd CRP (Table 3). In the subgroup without detectable
AC, significant correlations were observed between
CP-1 and age, total cholesterol, triglycerides, and CRP
Table 3). In a linear regression model that included all
ubjects, independent associations were observed between
og MCP-1 and older age, white race, hypertension, CRP,
nd smoking (Table 4).
ssociation between MCP-1 and subclinical atheroscle-
osis. The proportion of patients with detectable coronary
alcium increased in a stepwise fashion across quartiles of
CP-1, from 17.7% in the first quartile to 32.4% in the
ourth quartile (unadjusted p for trend0.0001) (Fig. 1). In
logistic regression model adjusting for traditional athero-
clerosis risk factors (male gender, smoking, diabetes, hy-
ercholesterolemia, hypertension, and family history of
AD) and for CRP, higher MCP-1 levels remained inde-
endently associated with CAC status. After further adjust-
ent for age, however, MCP-1 was no longer indepen-
ently associated with CAC (Table 5). When these analyses
ere repeated after excluding subjects receiving statin ther-
py, similar results were observed (data not shown).
ISCUSSION
n a large probability-based population sample, increasing
lasma concentrations of MCP-1 were associated with several
linical Variables (n  3,499)
Quartile 3 Quartile 4 p Trend
874 873
9 168–226.1 226.1
44 [36, 52] 47 [39, 54] 0.0001
400 (46) 398 (46) 0.05
421 (48) 438 (50) 0.0001
273 (31) 294 (34) 0.0001
158 (18) 125 (14) 0.26
22 (3) 16 (2) 0.95
298 (35) 360 (42) 0.0001
108 (12) 124 (14) 0.0001
2] 180 [156, 204] 181 [155, 208] 0.0002
] 98 [69, 151] 104 [74, 153] 0.0001
47 [39, 57] 47 [39, 56] 0.04
] 106 [85, 128] 108 [83, 130] 0.02
280 (32) 283 (32) 0.0001
286 (33) 317 (36) 0.002
5] 117 [96, 145] 113 [91, 143] 0.0001
85 (12) 104 (15) 0.33
26 (4) 21 (3) 0.51
28 [25, 33] 29 [25, 34] 0.01
33 [25, 40] 33 [24, 41] 0.59
] 3 [1.2, 6.9] 3.6 [1.4, 8.7] 0.0001
edian [25th, 75th percentile].
ce; DEXA  dual-energy X-ray absorbiometry; HDL  high-density lipoprotein
in cholesterol; LVEF  left ventricular ejection fraction; LVH  left ventricularand C
tile 2
77
–167.
, 51]
(48)
(48)
(30)
(20)
(2)
(31)
(11)
4, 20
, 146
, 56]
, 123
(26)
(32)
0, 14
(12)
(2)
, 33]
, 40]
3, 6.5
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November 2, 2004:1812–8 MCP-1 and Coronary Atherosclerosisypercholesterolemia, smoking, family history of premature
AD, lower creatinine clearance, and higher levels of CRP.
he MCP-1 levels were also higher in whites than African
mericans. These results extend previous observations among
atients with acute coronary syndromes (9,15–17) to a low-risk
opulation-based cohort. Similar findings were observed
mong patients with no evidence of CAC, suggesting that the
ssociation between MCP-1 and atherosclerosis risk factors
as not due to the presence of concomitant coronary athero-
clerosis. Although we cannot exclude the possibility that the
ssociation between risk factors and MCP-1 was due to
therosclerosis in noncoronary vascular beds, prior population-
able 3. Unadjusted Correlation Between MCP-1 Levels and
ontinuous Variables
Total Population
(n  3,499)
Patients With
CAC <10
(n  2,151)
Spearman  p Value Spearman  p Value
ge (yrs) 0.18 0.0001 0.12 0.0001
otal cholesterol 0.08 0.0001 0.05 0.02
DL 0.05 0.003 0.03 0.23
DL 0.04 0.01 0.04 0.09
riglycerides 0.14 0.0001 0.11 0.0001
rCl 0.06 0.0004 0.06 0.006
RP 0.10 0.0001 0.05 0.02
fat by DEXA 0.01 0.7 0.005 0.82
BP 0.08 0.0001 0.04 0.07
BP 0.02 0.2 0.003 0.89
eart rate 0.01 0.4 0.01 0.53
able 2. Association Between MCP-1 Levels and Demographic
therosclerosis (CAC score 10; n  2,151)
Quartile 1 Qu
ubjects (n) 538
ange (pg/ml) 120.7 120.
ge (yrs) 41 [35, 47] 41 [
ale gender 211 (38) 23
ace
Black 309 (57) 23
White 127 (24) 17
Hispanic 93 (17) 11
Other 9 (2) 1
edical history
Hypertension 142 (27) 12
Diabetes 36 (7) 4
Cholesterol (mg/dl) 175 [152, 200] 178 [
Triglycerides (mg/dl) 83 [60, 131] 96 [
HDL (mg/dl) 50 [41, 59] 47 [
LDL (mg/dl) 103 [82, 126] 105 [
Current smoker 111 (21) 13
Family history of CAD 148 (28) 14
CrCl (ml/min) 119 [99, 140] 119 [
LVH (n  1,983) 60 (12) 5
LVEF 55% (n  1,983) 12 (2)
BMI 28 [24, 32] 28 [
% fat by DEXA 33 [26, 40] 33 [
Median hs-CRP 2.4 [1, 5.7] 2.6 [
ategorical data are presented as number (percent) and continuous data are presente
Abbreviations as in Table 1.AC  coronary artery calcium; DBP  diastolic blood pressure; SBP  systolic
lood pressure; other abbreviations as in Table 1. Aased studies have demonstrated a very low prevalence of
oncoronary atherosclerosis in patients without detectable
AC (18). In a multivariable linear regression model, older
ge, white race, hypertension, CRP and smoking were inde-
endently associated with higher MCP-1 levels. Although
CP-1 and CRP were associated with each other, the
orrelation between these two inflammatory markers was
odest, suggesting that they reflect different inflammatory
athways.
In this study, MCP-1 was associated with CAC in
ultivariable analyses adjusting for traditional coronary risk
actors; however, when further adjustment was made for
ge, MCP-1 was no longer independently associated with
he presence of subclinical atherosclerosis. These results
uggest that MCP-1 may not be useful as a clinical tool that
s additive to the assessment of age, traditional risk factors,
nd/or CRP for the detection of subclinical atherosclerosis.
owever, our findings may have important pathophysio-
ogic implications.
able 4. Variables Independently Associated With Log MCP-1
n  2,777)
 Coefficient p Value
ge (per 10 yrs) 0.08 0.0001
hite race (vs. black race) 0.14 0.0001
ypertension 0.05 0.03
RP (per mg/l) 0.007 0.0001
moking 0.07 0.002
linical Variables in Subjects Without Evidence of Subclinical
2 Quartile 3 Quartile 4 p Trend
536 538
.8 163.9–220.8 220.8
] 42 [36, 49] 44 [37, 51] 0.0001
) 216 (41) 211 (42) 0.20
) 229 (43) 238 (44) 0.0001
) 185 (35) 192 (36) 0.0001
) 106 (20) 96 (18) 0.96
16 (3) 12 (2) 0.44
) 131 (25) 175 (33) 0.03
49 (9) 43 (8) 0.33
04] 181 [157, 206] 182 [156, 209] 0.0001
6] 98 [70, 151] 104 [74, 152] 0.0001
] 47 [39, 58] 48 [39, 56] 0.03
8] 107 [85, 130] 108 [83, 130] 0.13
) 149 (28) 155 (29) 0.0007
) 149 (28) 183 (34) 0.02
45] 117 [98, 143] 113 [92, 141] 0.01
) 38 (8) 57 (11) 0.49
7 (1) 12 (2) 0.90
] 28 [25, 32] 28 [25, 33] 0.35
] 34 [25, 41] 33 [24, 41] 0.80
.2] 2.7 [1.1, 5.7] 2.8 [1.1, 6.8] 0.01
edian [25th, 75th percentile].and C
artile
539
8–163
36, 48
4 (42
8 (44
1 (32
8 (22
3 (2)
9 (24
3 (8)
155, 2
66, 14
40, 56
82, 12
0 (24
6 (27
101, 1
1 (10
9 (2)
25, 32
25, 40
1.2, 6bbreviations as in Table 1.
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MCP-1 and Coronary Atherosclerosis November 2, 2004:1812–8athophysiologic implications. Initial evidence implicat-
ng MCP-1 in atherogenesis was developed in mouse
odels. In mice rendered susceptible to atherosclerosis by
nockout of the apolipoprotein E gene, overexpression of
CP-1 results in enhanced lipid staining and an increased
urden of macrophages in atherosclerotic lesions (19).
onversely, mice with MCP-1 gene deletions have less lipid
eposition and macrophage infiltration in their aortas than
o those with normal MCP-1 expression (6). Similarly,
eletion of the gene for the CCR-2 receptor (the ligand for
CP-1) also results in reduced atherosclerotic burden in
ouse models (7). These studies provide substantial evi-
ence for a role of MCP-1 in atherogenesis, yet the
nterplay between MCP-1 and traditional cardiovascular
isk factors has been less well defined.
Traditional cardiovascular risk factors may mediate some
f their effects on atherosclerosis via MCP-1 dependent
athways. Low-density lipoprotein upregulates CCR-2 re-
eptor expression, which enhances monocyte chemotaxis
20). In addition, minimally modified LDL (a non-
xidative degradation product of LDL) increases MCP-1
evels and monocyte activity (21). Animal models also reveal
educed MCP-1 levels and macrophage infiltration in the
igure 1. Association between quartiles of monocyte-chemoattractant
rotein-1 (MCP-1) and the prevalence of subclinical atherosclerosis
etected by electron beam computed tomography (coronary artery calcium
CAC] score 10).
able 5. Odds of Subclinical Atherosclerosis (CAC  10)
Model 1
OR [95% CI]
M
OR
CP quartile 2 1.30 [0.99–1.73] 1.29
CP quartile 3 1.60 [1.22–2.11] 1.41
CP quartile 4 2.02 [1.54–2.63] 1.58
ale gender — 2.76
ypertension — 3.11
iabetes — 2.16
ypercholesterolemia — 2.25
obacco use — 1.79
amily history of CAD — 1.67
RP (per mg/l) — 1.03
ge (per 10 yrs) —
odel 1: Unadjusted p trend across MCP-1 quartiles 0.0001; Model 2: Adjusted
raditional risk factors and age p trend across MCP-1 quartiles  0.40; Model 4: Adjusted
CI  confidence interval; CRP  C-reactive protein; OR  odds ratio; other abbreviaeointima and media of mice treated with HMG-CoA
eductase inhibitors (22). Finally, statin agents have been
hown to lower plasma levels of MCP-1 in humans (23).
We observed an independent association between hyper-
ension and MCP-1 levels. It is plausible that hypertension
ay also predispose humans to atherosclerosis in part via
ffects on MCP-1. Angiotensin II, which is upregulated in
ypertension, activates nuclear factor kappa-B, a regulator
f MCP-1 gene transcription (24). Angiotensin-converting
nzyme inhibitors, therefore, may exert atheroprotective
ffects in part by inhibiting MCP-1 transcription (25).
Smoking was also independently associated with MCP-1
evels in the present study. Cigarette smoking has been
hown to directly and indirectly activate macrophages to
elease MCP-1 in animal models and in humans with
hronic obstructive lung disease (26). Smoking may con-
ribute to atherosclerosis in part by modifying collagen and
ther vascular wall proteins so that they activate macro-
hages to secrete MCP-1. In addition, indirect effects, such
s oxidation or modification of LDL (27), may contribute to
he effects of smoking on MCP-1 levels.
Age is the variable most closely associated with MCP-1
evels in the present study. A previous study of healthy
ubjects showed an age-dependent increase in MCP-1
cross each decade of life (28). Although it could be argued
hat the plasma concentration of MCP-1 may reflect the
umulative burden of atherosclerosis, which is a function of
ge, the present study demonstrates that MCP-1 levels
ncrease with age even among those without evidence of
therosclerosis. Older age results in the formation of reac-
ive oxygen species and progression of vascular endothelial
ysfunction, both of which may occur via MCP-1–
ependent pathways (29,30). The strong correlation seen
etween increasing MCP-1 levels and older age among
atients with and without coronary calcification suggests
hat MCP-1 may mediate age-related effects on the vascu-
ature.
In summary, the finding that traditional cardiovascular
isk factors are associated with MCP-1 levels adds support
2
CI]
Model 3
OR [95% CI]
Model 4
OR [95% CI]
1.75] 1.18 [0.85–1.65] 1.14 [0.84–1.56]
1.90] 1.15 [0.83–1.60] 1.25 [0.92–1.69]
2.12] 1.14 [0.82–1.57] 1.31 [0.97–1.77]
3.43] 3.50 [2.75–4.46] —
3.84] 1.74 [1.37–2.20] —
2.87] 1.86 [1.37–2.54] —
2.93] 1.53 [1.14–2.04] —
2.22] 2.49 [1.96–3.17] —
2.06] 1.31 [1.05–1.65] —
1.05] 1.02 [1.00–1.04] —
3.84 [3.31–4.49] 3.73 [3.28–4.26]
ditional risk factors p trend across MCP-1 quartiles  0.05; Model 3: Adjusted forodel
[95%
[0.95–
[1.04–
[1.18–
[2.22–
[2.52–
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[1.44–
[1.36–
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—
for tra
for age p trend across MCP-1 quartiles  0.07.
tions as in Tables 1 and 3.
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November 2, 2004:1812–8 MCP-1 and Coronary Atherosclerosiso the hypothesis that MCP-1 may function in the causal
athway between risk factors and atherosclerosis, mediating
ome of the effects of these traditional risk factors. Thus,
CP-1 may have value in the future as a biomarker target
or drug development. Further experimental studies are
eeded to evaluate this hypothesis.
tudy limitations. Although this study represents the first
arge-scale evaluation of MCP-1 in a population-based
ohort, it has a number of important limitations. First, we
erformed EBCT as the measure of atherosclerosis burden
n the Dallas Heart Study. Given that age is so closely
ssociated with coronary calcification (31–34), this relation-
hip may have “dominated” a more subtle association
etween MCP-1 and CAC in multivariable models. Asso-
iation studies with MCP-1 should be performed using
ther measures of subclinical atherosclerosis that may be less
ependent on age, such as carotid intima-media thickness,
agnetic resonance imaging of the vascular wall, and novel
laque imaging modalities. Second, the cross-sectional de-
ign of the present study does not permit assessment of the
emporal associations among cardiovascular risk factors,
CP-1, and the development or progression of atheroscle-
osis. Many years would be required to analyze the longi-
udinal association between MCP-1 and the clinical com-
lications of atherosclerotic disease. Finally, we were not
ble to evaluate the association between MCP-1 and prog-
osis with a cross-sectional study design. Prospective studies
ith both clinical and imaging endpoints will be needed to
ully evaluate the clinical potential of MCP-1 as a biomarker
f atherosclerosis.
onclusions. In a population-based sample, plasma levels
f MCP-1 were associated with traditional cardiovascular
isk factors, both in subjects with and without evidence for
ubclinical coronary atherosclerosis. The association be-
ween MCP-1 levels and CAC was independent of tradi-
ional risk factors, but not of age. Based on sound experi-
ental evidence linking MCP-1 with the development of
therosclerosis, strong associations between MCP-1 levels
nd risk factors for atherosclerosis observed in the present
tudy, and prior demonstration that preventive therapies
ower MCP-1 levels (35,36), MCP-1 holds promise as a
iomarker target for drug development. Further prospective
tudies of this biomarker are warranted.
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